Rebecca G Wells

Yale University

$15,805,994

Attributed

$21,421,596

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.5M · FY2005–25

$2M$1.5M$1M$500K$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$21,421,596 · 13

By mechanism

R01$16,795,824 · 5

P30$2,095,443 · 4

U54$1,331,858 · 1

R56$1,198,471 · 3

Top collaborators

Paul A Janmey12 shared
Vivek Shenoy12 shared
Michael A Pack6 shared
John R Porter1 shared

Most similar at Yale University

Same institution · by research overlap

Jonathan A Dranoff$4,854,909

Others in their field

Top investigators on “Liver”

David Heimbrook · Leidos Biomedical Research, Inc.$183,557,534
Constance Ann Benson · University Of California, San Diego$65,790,143
Richard Douglas Moore · Johns Hopkins University$59,048,354
Paul M. Ridker · Brigham And Women'S Hospital$55,416,022
Michael S. Saag · University Of Alabama At Birmingham$50,288,385
Mark A Kay · Stanford University$49,905,067

Research focus

LiverCellsFibrosisLiver DiseasesCirrhosisTissuesMechanicsAffectLeadExtracellular MatrixResponseIn VivoPropertyFibroblastsPhenotypeIn VitroInjuryBaseLiver FibrosisInnovationInsightProgramsResearch PersonnelMyofibroblast

Grant awards (69)

Pathological consequences of altered tissue mechanics in fibrosis$652,816

R01 · FY2025 · EB · contact PI

Injury, Progression, and Fibrosis of the Extrahepatic Bile Duct$357,500

R01 · FY2025 · DK · contact PI

Pilot and Feasibility Grant Program$219,146

P30 · FY2025 · DK · contact PI

Enrichment Program$96,364

P30 · FY2025 · DK · contact PI

Pathological consequences of altered tissue mechanics in fibrosis$639,759

R01 · FY2024 · EB · contact PI

Injury, Progression, and Fibrosis of the Extrahepatic Bile Duct$343,200

R01 · FY2024 · DK · contact PI

Pilot and Feasibility Grant Program$219,146

P30 · FY2024 · DK · contact PI

Enrichment Program$96,364

P30 · FY2024 · DK · contact PI

Pathological consequences of altered tissue mechanics in fibrosis$652,816

R01 · FY2023 · EB · contact PI

Injury, Progression, and Fibrosis of the Extrahepatic Bile Duct$357,500

R01 · FY2023 · DK · contact PI

Pilot and Feasibility Grant Program$219,146

P30 · FY2023 · DK · contact PI

Enrichment Program$96,364

P30 · FY2023 · DK · contact PI

Pathological consequences of altered tissue mechanics in fibrosis$652,816

R01 · FY2022 · EB · contact PI

Injury, progression, and fibrosis of the extrahepatic bile duct$365,625

R01 · FY2022 · DK · contact PI

Pilot and Feasibility Grant Program$219,146

P30 · FY2022 · DK · contact PI

Enrichment Program$96,364

P30 · FY2022 · DK · contact PI

Pathological consequences of altered tissue mechanics in fibrosis$491,086

R01 · FY2021 · EB · contact PI

Injury, progression, and fibrosis of the extrahepatic bile duct$365,625

R01 · FY2021 · DK · contact PI

Pilot & Feasibility Program$190,276

P30 · FY2021 · DK · contact PI

Enrichment Program$93,275

P30 · FY2021 · DK · contact PI

Pathological consequences of altered tissue mechanics in fibrosis$501,109

R01 · FY2020 · EB · contact PI

Injury, progression, and fibrosis of the extrahepatic bile duct$364,500

R01 · FY2020 · DK · contact PI

Pilot & Feasibility Program$185,101

P30 · FY2020 · DK · contact PI

Enrichment Program$88,099

P30 · FY2020 · DK · contact PI

Pathological consequences of altered tissue mechanics in fibrosis$501,109

R01 · FY2019 · EB · contact PI

Injury, progression, and fibrosis of the extrahepatic bile duct$364,500

R01 · FY2019 · DK · contact PI

Core 1: Cell and Tissue Core$249,648

U54 · FY2019 · CA · contact PI

Pilot & Feasibility Program$186,826

P30 · FY2019 · DK · contact PI

Enrichment Program$89,826

P30 · FY2019 · DK · contact PI

Pathological consequences of altered tissue mechanics in fibrosis$501,109

R01 · FY2018 · EB · contact PI

Injury, progression, and fibrosis of the extrahepatic bile duct$402,500

R56 · FY2018 · DK · contact PI

Core 1: Cell and Tissue Core$263,761

U54 · FY2018 · CA · contact PI

Pathological consequences of altered tissue mechanics in fibrosis$432,811

R01 · FY2017 · EB · contact PI

Core 1: Cell and Tissue Core$276,357

U54 · FY2017 · CA · contact PI

Pathological consequences of altered tissue mechanics in fibrosis$432,811

R01 · FY2016 · EB · contact PI

TGF-beta, matrix, and myofibroblasts in hepatic fibrosis$342,258

R01 · FY2016 · DK · contact PI

Core 1: Cell and Tissue Core$267,114

U54 · FY2016 · CA · contact PI

Isolation, Identification and Characterization of a Toxin Causing Biliary Atresia$447,971

R56 · FY2015 · DK · contact PI

Pathological consequences of altered tissue mechanics in fibrosis$424,155

R01 · FY2015 · EB · contact PI

TGF-beta, matrix, and myofibroblasts in hepatic fibrosis$342,258

R01 · FY2015 · DK · contact PI

Core 1: Cell and Tissue Core$274,978

U54 · FY2015 · CA · contact PI

Isolation, Identification and Characterization of a Toxin Causing Biliary Atresia$507,197

R01 · FY2014 · DK · contact PI

Pathological consequences of altered tissue mechanics in fibrosis$432,811

R01 · FY2014 · EB · contact PI

TGF-beta, matrix, and myofibroblasts in hepatic fibrosis$342,258

R01 · FY2014 · DK · contact PI

Isolation, Identification and Characterization of a Toxin Causing Biliary Atresia$489,444

R01 · FY2013 · DK · contact PI

TGF-beta, matrix, and myofibroblasts in hepatic fibrosis$330,279

R01 · FY2013 · DK · contact PI

Isolation, Identification and Characterization of a Toxin Causing Biliary Atresia$515,942

R01 · FY2012 · DK · contact PI

TGF-beta, matrix, and myofibroblasts in hepatic fibrosis$342,258

R01 · FY2012 · DK · contact PI

Isolation, Identification and Characterization of a Toxin Causing Biliary Atresia$137,366

R01 · FY2012 · DK · contact PI

Isolation, Identification and Characterization of a Toxin Causing Biliary Atresia$563,684

R01 · FY2011 · DK · contact PI

Mechanisms of fibrosis in pediatric liver diseases$348,000

R56 · FY2011 · DK · contact PI

TGF-beta, matrix, and myofibroblasts in hepatic fibrosis$313,253

R01 · FY2010 · DK · contact PI

TGF-beta, matrix, and myofibroblasts in hepatic fibrosis$316,418

R01 · FY2009 · DK · contact PI

TGF-beta, matrix, and myofibroblasts in hepatic fibrosis$238,979

R01 · FY2009 · DK · contact PI

TGF-beta, matrix, and myofibroblasts in hepatic fibrosis$99,982

R01 · FY2009 · DK · contact PI

TGF-beta, matrix, and myofibroblasts in hepatic fibrosis$16,972

R01 · FY2009 · DK · contact PI

TGF-beta, matrix, and myofibroblasts in hepatic fibrosis$316,418

R01 · FY2008 · DK · contact PI

Betaglycan as a modulator of TGF-beta signaling in hepatoma$235,648

R01 · FY2008 · DK · contact PI

TGF-beta, matrix, and myofibroblasts in hepatic fibrosis$322,534

R01 · FY2007 · DK · contact PI

Betaglycan as a modulator of TGF-beta signaling in hepatoma$240,459

R01 · FY2007 · DK · contact PI

Betaglycan as a modulator of TGF-b signaling in hepatoma$247,640

R01 · FY2006 · DK · contact PI

Betaglycan as a modulator of TGF-b signaling in hepatoma$253,600

R01 · FY2005 · DK

TGF-B Mediated Fibrosis in a Hepatic Stellate Cell Model$235,769

R01 · FY2005 · DK

Betaglycan as a modulator of TGF-b signaling in hepatoma$253,600

R01 · FY2004 · DK

TGF-B Mediated Fibrosis in a Hepatic Stellate Cell Model$235,769

R01 · FY2004 · DK

TGF-B Mediated Fibrosis in a Hepatic Stellate Cell Model$235,769

R01 · FY2003 · DK

TGF-B Mediated Fibrosis in a Hepatic Stellate Cell Model$165,344

R01 · FY2002 · DK

TGF-B Mediated Fibrosis in a Hepatic Stellate Cell Model$77,862

R01 · FY2002 · DK

TGF-B Mediated Fibrosis in a Hepatic Stellate Cell Model$243,206

R01 · FY2001 · DK